71
Participants
Start Date
September 29, 2020
Primary Completion Date
May 29, 2024
Study Completion Date
October 23, 2024
Lorlatinib
25 milligram (mg) tablet
Kantonsspital Graubuenden, Chur
AOU San Luigi Gonzaga, Orbassano (TO)
Hospital Teresa Herrera (C.H.U.A.C), A Coruña
IRCCS Ospedale San Raffaele, Milan
Fondazione IRCCS San Gerardo dei Tintori, Monza
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda
Hospital Regional Universitario de Malaga, Málaga
Centro Riferimento Oncologico di Aviano - IRCCS SOC Oncologia Medica e dei Tumori Immunocorrelati, Aviano
Hospital Universitario Virgen del Rocio, Seville
Azienda Ospedaliero Universitaria di Parma, Parma
Hospital Universitari i Politecnic La Fe, Valencia
Azienda Ospedaliera San Giuseppe Moscati, Avellino
UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi
Bhakti Vedanta Hospital and Research Institute, Thāne
Healthcare Global Enterprises, Bengaluru
Azienda Ospedaliera San Camillo Forlanini, Roma
AO Santa Maria della Misericordia, Perugia
Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna, Lublin
Centrum Medyczne EVOMED, Szczecin
Dom Lekarski Centrum Medyczne Outlet Park, Szczecin
Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ, Szczecin
Dom Lekarski S.A., Szczecin
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
ICO L'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat
Guy's and St Thomas' NHS Foundation Trust, London
NIHR/Wellcome Trust Clinical Research Facility, Manchester
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Pfizer
INDUSTRY